1Yoshida Y,Hagura R,Hara Y,et al.Risk factors for the development of diabetic retinopathy in Japanese type 2 diabetic patients.Diabetes Res clin pract[J],2001,51:195 ~ 203
2Abiko T,abiko A,Clermont AC,et al.characterization of retinal leukostasis and hemodynamics in insulin resistance and diabetes:role of oxidants and protein kinase C activation.Diabetes,2003,52(3):829 ~ 837
3Suzuma k,Takahara N,Suzuma I,et al.characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation,vascular endothelial growth factor induced endothelial proliferation and retinal neovascularization.proc Natl Acad sci USA 2002,99(2):721 ~ 207
6Stefansson E.therapeutic effects of retinal laser treatment and Vitrectomy.A theory based on oxygen and vascular physiology.A cta ophthalmol scand 2001,79:435 ~ 440
7Blar NP.Ocular oxygen consumption during Vitrectomy perfusion in the cat.trans Am ophthalmol soc 2000,98:305 ~ 329
8Otani T,kishi s.A Controlled study of vitrectomy for diabetic Macular edema.AM J ophthalmol,2002,134:214 ~ 219
9Kadonosono k,Itoh v,Ohna s.Microcirculation before and after vitrectomy for diabetic cystoid macular edema.AM J ophthalmol,2002,130:700~ 744
二级参考文献28
1Yokota T, Ma RC, Park JY,et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes, 2003, 52 (3) :838-845.
2Xia P, Aiello LP, Ishii H,et al. Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C,its isoforms, and endothelial cell growth. J Clin Invest, 1996, 98(9) :2018-2026.
3Suzuma K, Takahara N, Suzuma I, et al. Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Na
4Grant MB, Mares RN, Fitzgerald C, et al. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. Diabetes Care,2000, 23 (4) :504-509.
5Seo MS, Kwak N, Ozaki H, et al. Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor. Am J Pathol, 1999, 154 (6): 1743-1753.
6Chaturvedi N, Sjolie AK, Stephenson JM, et al. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet, 1998, 9095(351) :28-31.
7Freedman BI , WuerthJP, Cartwright K, et al. Design and baseline characteristics for the aminoguanidine Clinical Trial in Overt Type 2Diabetic Nephropathy (ACTION II). Control Clin Trials, 1999, 20(5):493-510.
8Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol, 1985, 103(12): 1796-806.
9Way KJ, Chou E, King GL. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci,2000, 21 (5):181-187.
10Koya D, King GL. Protein kinase C activation and the development of diabetic complications. Diabetes, 1998, 47 (6) :859-866.